nebulized epinephrine — Competitive Intelligence Brief

nebulized epinephrine (nebulized epinephrine) competitive landscape: 5 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic amine / Adrenergic agonist. Area: Pulmonology / Emergency Medicine.

marketed Sympathomimetic amine / Adrenergic agonist Alpha-1 and beta-2 adrenergic receptors Pulmonology / Emergency Medicine Small molecule

Target snapshot

nebulized epinephrine (nebulized epinephrine) — Oman Medical Speciality Board. Nebulized epinephrine is an inhaled alpha and beta-adrenergic agonist that rapidly constricts airway blood vessels and relaxes bronchial smooth muscle to reduce airway edema and improve airflow.

Comparator set (5 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
nebulized epinephrine TARGET	nebulized epinephrine	Oman Medical Speciality Board	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 and beta-2 adrenergic receptors
Bupivacaine-epinephrine	Bupivacaine-epinephrine	Lumbini Medical College	marketed	Local anesthetic with vasopressor	Voltage-gated sodium channels; alpha-1 and beta-2 adrenergic receptors
Norepinephrine intra-arteriel/hepatic	Norepinephrine intra-arteriel/hepatic	University Health Network, Toronto	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-1 adrenergic receptor
ephedrine and phenylephrine	ephedrine and phenylephrine	University Hospital, Clermont-Ferrand	marketed	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, beta-1 adrenergic receptor, beta-2 adrenergic receptor
Epinephrine concentration of 1:1000000	Epinephrine concentration of 1:1000000	Al-Azhar University	phase 3	Sympathomimetic amine / Adrenergic agonist	Alpha-1, alpha-2, beta-1, and beta-2 adrenergic receptors
Epinephrine HFA-MDI (E004)	Epinephrine HFA-MDI (E004)	Amphastar Pharmaceuticals, Inc.	phase 3	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic amine / Adrenergic agonist class)

1. Al-Azhar University · 1 drug in this class
2. Amphastar Pharmaceuticals, Inc. · 1 drug in this class
3. Oman Medical Speciality Board · 1 drug in this class
4. University Health Network, Toronto · 1 drug in this class
5. University Hospital, Clermont-Ferrand · 1 drug in this class